• Journal of Preventive Medicine and Public Health
• /
• 제53권2호
• /
• pp.67-69
• /
• 2020

Controversy remains over whether the coronavirus disease 2019 (COVID-19) virus may have infectivity during the incubation period before the onset of symptoms. The author had the opportunity to examine the infectivity of COVID-19 during the incubation period by conducting an epidemiological survey on a confirmed patient who had visited Jeju Island during the incubation period. The epidemiological findings support the claim that the COVID-19 virus does not have infectivity during the incubation period.

• Clinical and Experimental Pediatrics
• /
• 제64권4호
• /
• pp.157-164
• /
• 2021

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, a small number of coronavirus disease 2019 (COVID-19) cases in neonates have been reported worldwide. Neonates currently account for only a minor proportion of the pediatric population affected by COVID-19. Thus, data on the epidemiological and clinical features of COVID-19 in neonates are limited. Approximately 3% of neonates born to mothers with COVID-19 reportedly tested positive for SARS-CoV-2. Current limited data on neonates with COVID-19 suggest that neonatal COVID-19 shows a relatively benign course despite a high requirement for mechanical ventilation. However, neonates with pre-existing medical conditions and preterm infants appear to be at a higher risk of developing severe COVID-19. The greatest perinatal concern of the COVID-19 pandemic is the possibility of vertical transmission, especially transplacental transmission of SARS-CoV-2. Although direct evidence of the vertical transmission of SARS-CoV-2 is lacking, its possibility during late pregnancy cannot be ruled out. This review summarizes available case studies on COVID-19 in neonates and introduces what is currently known about neonatal COVID-19 with focus on its vertical transmission.

• Clinical and Experimental Pediatrics
• /
• 제63권4호
• /
• pp.125-132
• /
• 2020

Coronavirus disease-2019 (COVID-19), which started in Wuhan, China, in December 2019 and declared a worldwide pandemic on March 11, 2020, is a novel infectious disease that causes respiratory illness and death. Pediatric COVID-19 accounts for a small percentage of patients and is often milder than that in adults; however, it can progress to severe disease in some cases. Even neonates can suffer from COVID-19, and children may spread the disease in the community. This review summarizes what is currently known about COVID-19 in children and adolescents.

• Pediatric Infection and Vaccine
• /
• 제27권1호
• /
• pp.11-23
• /
• 2020

2019년 12월 발견되어 2020년 3월 11일 전 세계 대유행이 선포된 코로나바이러스감염증-2019 (coronavirus disease-2019, COVID-19)는 신종 감염병으로서 수많은 감염사례와 사망을 초래하여 사회 전반적으로 영향을 끼치고 있다. 소아청소년 COVID-19는 발병 환자 중 차지하는 비율이 적으며 성인보다는 경증인 경우가 많으나, 일부에서는 중증으로 진행할 수 있다. 신생아 시기부터 감염될 수 있으며, 지역사회 감염의 전파자로서 역할을 할 수 있을 것으로 보인다. 본 종설에서는 현재까지 소아청소년에서의 COVID-19에 대해 알려진 내용을 정리하여 소아청소년 환자들의 진료에 도움을 주고자 한다.

• Korean Journal of Radiology
• /
• 제21권5호
• /
• pp.545-549
• /
• 2020

The 2019 novel coronavirus (2019-nCoV) outbreak in Wuhan, Hubei Province, China in 2019 led to large numbers of people being infected and developing atypical pneumonia (coronavirus disease 2019, COVID-19). Typical imaging manifestations of patients infected with 2019-nCoV has been reported, but we encountered an atypical radiological manifestation on baseline computed tomography (CT) images in three patients from Wuhan, China infected with the 2019-nCoV. Surprisingly, the only similar CT finding was a solitary sub-centimeter ground-glass nodule adjacent to bronchovascular bundles, which could be easily overlooked. In addition, the follow-up images in these patients showed how COVID-19 pneumonia evolved from these small nodules. The radiologic manifestation of the three cases will expand contemporary understanding of COVID-19.

• 대한한방내과학회지
• /
• 제43권1호
• /
• pp.41-52
• /
• 2022

Objectives: The purpose of this study is to investigate recent trends in randomized controlled trials (RCTs) on the treatment of Coronavirus disease 2019 (COVID-19) patients with traditional Chinese medicine (TCM) and analyze the results for the activation of COVID-19 Korean medicine research. Methods: We searched for RCTs published from December 2019 to October 2021 in the Chinese National Knowledge Infrastructure Database (CNKI). The investigation focused on the type of study, the purpose of the study, and the treatment methods. Results: A total of 8 RCTs were selected and analyzed from the 447 searched studies. All studies attempted to observe the effects of herbal medicine. Herbal medicine included granules, decoctions, and intravenous injections. The most frequently used herb type was drugs for clearing away heat and detoxification and releasing the exterior syndrome. In most studies, the effectiveness of TCM treatment of COVID-19 was significantly high. Conclusions: Although more quality studies are needed to support these results, TCM treatment for COVID-19 has been effective. Therefore, we hope that Korean medicine studies on infectious diseases will be actively conducted like TCM and contribute to national health.

• Archives of Plastic Surgery
• /
• 제49권5호
• /
• pp.611-613
• /
• 2022

The coronavirus disease 2019 (COVID-19) pandemic has been challenging in all aspects of the medical field with new clinical presentations constantly arising. Plastic surgeons are not immune to this and need to be aware of their implications. There has been a recent report of late periprosthetic seroma (breast implant) as a clinical manifestation of COVID-19 infection. To our knowledge, this phenomenon has not been further reported. We present a 53-year-old immunocompromised lady who developed late seroma after COVID-19 infection. She eventually required explantation of the implant and is awaiting autologous reconstruction. It is likely that we will increasingly continue to see this phenomenon of implant complications as a result of COVID-19 infection and should be watchful, especially regarding potential immunocompromised patients.

• Journal of Medicine and Life Science
• /
• 제17권2호
• /
• pp.33-40
• /
• 2020

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Genetic sequencing of the virus suggests that it is a beta coronavirus closely linked to the SARS virus. This disease has non-specific symptoms such as fever, dry cough, sore throat, and gastrointestinal symptoms. This virus can transmit via aerosol and need to droplet precaution to prevent spreading in public areas. Most people with COVID-19 develop only mild or uncomplicated illness. However, about 20% patients require hospitalization, oxygen supply, and intensive care. There is no currently effective treatment available for COVID-19 unresponsive to supportive care. This is review about the recently published epidemiologic, and clinical features, diagnosis, treatment and prevention of COVID-19.

• Tuberculosis and Respiratory Diseases
• /
• 제84권1호
• /
• pp.22-34
• /
• 2021

The coronavirus pandemic, known as coronavirus disease 2019 (COVID-19), is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in patients from Wuhan, China. Since December 2019, SARS-CoV-2 has spread swiftly around the world, infected more than 25 million people, and caused more than 800,000 deaths in 188 countries. Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) appear to be risk factors for COVID-19, however, their prevalence remains controversial. In fact, studies in China reported lower rates of chronic respiratory conditions in patients with COVID-19 than in the general population, while the trend is reversed in the United States and Europe. Although the underlying molecular mechanisms of a possible interaction between COVID-19 and chronic respiratory diseases remain unknown, some observations can help to elucidate them. Indeed, physiological changes, immune response, or medications used against SARS-CoV-2 may have a greater impact on patients with chronic respiratory conditions already debilitated by chronic inflammation, dyspnea, and the use of immunosuppressant drugs like corticosteroids. In this review, we discuss importance and the impact of COVID-19 on asthma and COPD patients, the possible available treatments, and patient management during the pandemic.

• 보건행정학회지
• /
• 제31권1호
• /
• pp.1-4
• /
• 2021

With this as a momentum of approval Pfizer vaccine against coronavirus disease 2019 (COVID-2019), it is changed to the era of vaccine rapidly. Most countries are trying to reserve effective vaccines and inoculate vaccines into high-risk populations for achieving community immunity. I reviewed several vaccine-related issues to be confronted for moving up to the end of COVID-2019: the efficacy and effectiveness of the approved vaccines, the priorities for vaccination into target groups, side effects, and distrust towards COVID-2019 vaccines. Evidence-based decision-making in the policy process and collaboration with professional groups are the most effective strategies for driving successful vaccination policy.